Gene-modified NK cells expressing CD64 and preloaded with HIV-specific BNAbs target autologous HIV-1–infected CD4+ T cells by ADCC
The Journal of Immunology · 01.02.2025 · 214 (2) · 253-264
DOI: 10.1093/jimmun/vkae028 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 17.02.2025. Verfasst von Costin Tomescu und 5 weiteren Autor:innen. Beteiligte Einrichtung: HIV Immunopathogenesis Laboratory, BEAT-HIV Delaney Collaboratory, Wistar Institute, Philadelphia, PA, United States. Hauptthemen laut MEDLINE: Killer Cells, Natural, HIV-1, HIV Infections, Receptors, IgG. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI, NIDDK, NIAID NIH HHS.
Abstract (Originalsprache)
Natural killer (NK) cells can efficiently mediate antibody-dependent cellular cytotoxicity (ADCC) of antibody coated target cells via the low-affinity Fc-receptor, CD16, but cannot retain antibodies over time. To increase antibody retention and facilitate targeted ADCC, we genetically modified human NK cells with the high-affinity Fc receptor, CD64, so that we could preload them with HIV-specific broadly neutralizing antibodies (BNAbs) and enhance their capacity to target HIV-infected cells via ADCC. Purified NK cells from the peripheral blood of control donors or persons living with HIV were activated with interleukin (IL)-2/IL-15/IL-21 cytokines and transduced with a lentivirus encoding CD64. High levels of CD64 surface expression were maintained for multiple weeks on NK cells and CD64-transduced NK cells were phenotypically similar to control NK cells with strong expression of CD56, CD16, NKG2A, NKp46, CD69, HLA-DR, CD38, and CD57. CD64-transduced NK cells exhibited significantly greater capacity to bind HIV-specific BNAbs in short-term antibody binding assay as well as retain the BNAbs over time (1-wk antibody retention assay) compared with control NK cells only expressing CD16. BNAb-preloaded CD64-transduced NK cells showed a significantly enhanced capacity to mediate ADCC against autologous HIV-1–infected CD4+ primary T cells in both a short-term 4 h degranulation assay as well as a 24 h HIV p24 HIV elimination assay when compared with control NK cells. A chimeric CD64 enhanced NK cell strategy (NuKEs [NK Enhancement Strategy]) retaining bound HIV-specific BNAbs represents a novel autologous primary NK cell immunotherapy strategy against HIV through targeted ADCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HIV Immunopathogenesis Laboratory, BEAT-HIV Delaney Collaboratory, Wistar Institute, Philadelphia, PA, United States.
- Molecular Screening and Protein Expression Facility, Wistar Institute, Philadelphia, PA, United States.
- Center for Cellular Immunotherapies, BEAT-HIV Delaney Collaboratory, Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.
ORCID-Profile: Adiana Ochoa-Ortiz, Luis J Montaner
Förderung
- NHLBI
- NIDDK
- NIAID NIH HHS
- NCI NIH HHS
- NINDS
- NIDA
- NIAID
- amfAR
Zitieren
APA
Tomescu, C., Ochoa-Ortiz, A., Lu, L. D., Kong, H., Riley, J. L., & Montaner, L. J. (2025). Gene-modified NK cells expressing CD64 and preloaded with HIV-specific BNAbs target autologous HIV-1–infected CD4+ T cells by ADCC. The Journal of Immunology, 214(2), 253-264. https://doi.org/10.1093/jimmun/vkae028
Vancouver
Tomescu C, Ochoa-Ortiz A, Lu LD, Kong H, Riley JL, Montaner LJ. Gene-modified NK cells expressing CD64 and preloaded with HIV-specific BNAbs target autologous HIV-1–infected CD4+ T cells by ADCC. The Journal of Immunology. 2025;214(2):253-264. doi:10.1093/jimmun/vkae028
BibTeX
@article{Tomescu2025,
author = {Tomescu, Costin and Ochoa-Ortiz, Adiana and Lu, Lily D and Kong, Hong and Riley, James L and Montaner, Luis J},
title = {Gene-modified NK cells expressing CD64 and preloaded with HIV-specific BNAbs target autologous HIV-1–infected CD4+ T cells by ADCC},
journal = {The Journal of Immunology},
year = {2025},
volume = {214},
number = {2},
pages = {253--264},
doi = {10.1093/jimmun/vkae028}
}
EUVIMED